Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis
Paul D. Miller(Colorado Center for Bone Research), Claus Christiansen(VA Eastern Colorado Health Care System), Felicia Cosman(Helen Hayes Hospital), Gary Hattersley(Radius Health (United States)), Lorraine A. Fitzpatrick(Albury Wodonga Health), Peter Alexandersen(Center for Clinical & Basic Research), Cristiano A. F. Zerbini(Centro Paulista de Investigação Clinica), Edith Lau, Gregory C. Williams(Radius Health (United States)), Luis Augusto Tavares Russo, Bente Juel Riis(Nordic Bioscience (Denmark)), Alan G. Harris(Radius Health (United States)), Ming‐yi Hu(Radius Health (United States))
Cited by 845
Related Papers
Clinician’s Guide to Prevention and Treatment of Osteoporosis
|Osteoporosis International|2014|4.1k
The diagnosis of osteoporosis
|Journal of Bone and Mineral Research|1994|3.9k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.4k
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes
|Nature Genetics|2006|2.3k
Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women
|New England Journal of Medicine|1997|1.6k